Table 3.
Number of patients with severe asthma exacerbations in each poly-C repeat genotype group
| Poly-C genotype | 10a/ 11a | 10a/ 12a | 11a/ 11a | 10a/ 13b | 11a/ 12a | 11a/ 13b | 12a/ 12a | 11a/ 14b | 12a/ 13b | 12a/ 14b | 13b/ 13b | 13b/ 14b | Genotypes <1% | Undetermined |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients, n |
44 |
57 |
225 |
62 |
314 |
418 |
136 |
74 |
356 |
75 |
211 |
119 |
98 |
58 |
| Patients with ≥1 severe exacerbation, n (%) |
4 (9) |
3 (5) |
26 (12) |
5 (8) |
29 (9) |
48 (11) |
12 (9) |
10 (14) |
32 (9) |
14 (19) |
21 (10) |
19 (16) |
13 (13) |
7 (12) |
| Total number of severe exacerbations |
4 |
3 |
50 |
8 |
43 |
66 |
14 |
12 |
39 |
25 |
25 |
22 |
16 |
21 |
| Number of exacerbations per patient/6 months | 0.13 | 0.06 | 0.32 | 0.14 | 0.15 | 0.24 | 0.11 | 0.18 | 0.13 | 0.37 | 0.16 | 0.20 | 0.18 | 0.39 |
Severe exacerbations were defined as deterioration in asthma leading to hospitalization, emergency department treatment, or oral glucocorticosteroid treatment lasting three or more days. Data includes all patients with available data of all races and all treatment arms combined (total n = 2,247; all patients with data postrandomization).